|
|
|
|
In the Loop: Continuous Chromatography for Chiral (and Other) Separations
With single-enantiomer separations dominating the blockbuster
charts, simulated moving bed chromatography and other multicolumn
continuous chromatographic processes offer a quick route to
clinical trial materials, along with the resolution, economy, and
scalability to support tons-per-year production.
|
| |
More>>
|
|
|
|
|
|
The Virtual Revolution (The Time Is Now)
Several environmental factors have recently emerged that are drastically affecting pharmaceutical research and development. The costs associated with the development of a new molecular entity are increasing. In 2003, the Tufts Center for The Study of Drug Development estimated the development costs at $897 million dollars.
|
| |
More>>
|
|
|
|
|
|
By the Numbers: What it Costs to Operate a Biopharmaceutical Facility
Operating costs are the white-hot issue in the boardrooms of life sciences companies and they tend to rule the site selection process. A soft economy, worldwide trade competition, drug cost containment pressures from the US government, and a lean and mean message sent by the venture capital community mean that quantitative factors that focus on the cost of doing business are trumping qualitative lifestyle factors, especially when evaluating sites for a new biopharmaceutical facility.
|
| |
More>>
|
|
|
|
|
|
Introduction: An Overview of Intellectual Property
Intellectual property is, by definition, a group of intangible rights that lay claim to products of human intellect. While the following list is not exhaustive, the main categories of intellectual property are: patent, copyright, trademark, and trade secret. Some of these rights, such as patent and copyright, are mentioned in the United States Constitution, where Congress is authorized "to promote the Progress of Science and the useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries."
|
| |
More>>
|
|
|
